Bispecific CAR T Cell Therapy Targeting BCMA and CD19 in Relapsed/Refractory Multiple Myeloma: A Phase I/II Trial

Scientists designed bispecific BC19 CAR T cells targeting BCMA/CD19 and evaluated antimyeloma activity in vitro and in vivo. Preclinical results indicated that BC19 CAR specifically recognized target antigens, and BC19 CAR T cells mediate selective killing of BCMA or CD19-positive cancer cells.